Why we need public-private partnerships in drug RandD

Why we need public-private partnerships in Life Sciences R&D

Laura Carrera Carballés Posted 11 June 2019

Only recently, the life science industry opened up to Research & Development (R&D) projects through public-private partnerships (PPPs). A logical evolution, since such approach allows to leverage impact and possible breakthroughs in cases it is the only way to move forward.

A clear example on how PPPs benefit the R&D field is the Innovative Medicines Initiative (IMI), a partnership between the European Union and the European pharmaceutical industry to facilitate research collaboration for the development of medicines, especially in areas of unmet medical need. More than 100 projects have benefited from this unique set-up, leading to over 3800 publications.

Many of these projects are in the field of Alzheimer's Disease, accounting for over 250 million euros. After many years of clinical trial failure in this field, pharmaceutical companies are now working together with the public sector, imaging companies and patient organizations to set up game-changing projects that approach Alzheimer's Disease from a different perspective.

An example of this is the European Prevention of Alzheimer's Dementia (EPAD) project, an IMI project with 39 institutions closely collaborating together to create a novel platform to run phase II studies for secondary prevention of Alzheimer's Dementia.  

READ THE FULL ARTICLE (Source: PharmaBoardRoom)

Modis provides grant writing & application support, and project management services to more than 20 public-private partnerships. We believe that - by combining expertise and by collaborating - we will be able to make real progress and bring innovative therapies and diagnostics to the market.

Laura Carrera Carbellés, Project Manager Life SciencesModisTweet this

Interested in our expertise in this field?

Please do not hesitate to get in touch with us!

Get in touch